Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.

Perera TPS, Jovcheva E, Mevellec L, Vialard J, De Lange D, Verhulst T, Paulussen C, Van De Ven K, King P, Freyne E, Rees DC, Squires M, Saxty G, Page M, Murray CW, Gilissen R, Ward G, Thompson NT, Newell DR, Cheng N, Xie L, Yang J, Platero SJ, Karkera JD, Moy C, Angibaud P, Laquerre S, Lorenzi MV.

Mol Cancer Ther. 2017 Jun;16(6):1010-1020. doi: 10.1158/1535-7163.MCT-16-0589. Epub 2017 Mar 24.

2.

Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.

Crescenzo R, Abate F, Lasorsa E, Tabbo' F, Gaudiano M, Chiesa N, Di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, Todaro M, Boi M, Acquaviva A, Ficarra E, Novero D, Rinaldi A, Tousseyn T, Rosenwald A, Kenner L, Cerroni L, Tzankov A, Ponzoni M, Paulli M, Weisenburger D, Chan WC, Iqbal J, Piris MA, Zamo' A, Ciardullo C, Rossi D, Gaidano G, Pileri S, Tiacci E, Falini B, Shultz LD, Mevellec L, Vialard JE, Piva R, Bertoni F, Rabadan R, Inghirami G; European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium “Genetics-Driven Targeted Management of Lymphoid Malignancies”.

Cancer Cell. 2015 Apr 13;27(4):516-32. doi: 10.1016/j.ccell.2015.03.006. Erratum in: Cancer Cell. 2015 May 11;27(5):744.

3.

Activation of RAS family members confers resistance to ROS1 targeting drugs.

Cargnelutti M, Corso S, Pergolizzi M, Mévellec L, Aisner DL, Dziadziuszko R, Varella-Garcia M, Comoglio PM, Doebele RC, Vialard J, Giordano S.

Oncotarget. 2015 Mar 10;6(7):5182-94.

4.

Structure-Based Design of Type II Inhibitors Applied to Maternal Embryonic Leucine Zipper Kinase.

Johnson CN, Adelinet C, Berdini V, Beke L, Bonnet P, Brehmer D, Calo F, Coyle JE, Day PJ, Frederickson M, Freyne EJ, Gilissen RA, Hamlett CC, Howard S, Meerpoel L, Mevellec L, McMenamin R, Pasquier E, Patel S, Rees DC, Linders JT.

ACS Med Chem Lett. 2014 May 23;6(1):31-6. doi: 10.1021/ml5001273. eCollection 2015 Jan 8.

5.

Impact on farnesyltransferase inhibition of 4-chlorophenyl moiety replacement in the Zarnestra series.

Angibaud P, Mevellec L, Meyer C, Bourdrez X, Lezouret P, Pilatte I, Poncelet V, Roux B, Merillon S, End DW, Van Dun J, Wouters W, Venet M.

Eur J Med Chem. 2007 May;42(5):702-14. Epub 2007 Jan 9.

PMID:
17316920
6.

Substituted azoloquinolines and -quinazolines as new potent farnesyl protein transferase inhibitors.

Angibaud P, Bourdrez X, End DW, Freyne E, Janicot M, Lezouret P, Ligny Y, Mannens G, Damsch S, Mevellec L, Meyer C, Muller P, Pilatte I, Poncelet V, Roux B, Smets G, Van Dun J, Van Remoortere P, Venet M, Wouters W.

Bioorg Med Chem Lett. 2003 Dec 15;13(24):4365-9.

PMID:
14643327
7.

4-methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA.

Angibaud P, Saha AK, Bourdrez X, End DW, Freyne E, Lezouret P, Mannens G, Mevellec L, Meyer C, Pilatte I, Poncelet V, Roux B, Smets G, Van Dun J, Venet M, Wouters W.

Bioorg Med Chem Lett. 2003 Dec 15;13(24):4361-4.

PMID:
14643326
8.

A new synthesis of 2-azabicyclo[2.1.1]hexanes.

Lescop C, Mévellec L, Huet F.

J Org Chem. 2001 Jun 15;66(12):4187-93.

PMID:
11397152

Supplemental Content

Loading ...
Support Center